Preclinical Oxygen Imager to Model Efficient Cancer Treatment

临床前氧成像仪可模拟有效的癌症治疗

基本信息

批准号：
9974497
负责人：
Mrignayani Kotecha
金额：
$ 83.16万
依托单位：
O2M TECHNOLOGIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-08 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9974497
关键词：
3-Dimensional Aerobic Allografting Animal Experimentation Animals Breast Cancer Model Cancer Biology Cells Certificate of Need Certification Chicago Clinic Communication Communities Complex Computer software Data Development Device or Instrument Development Devices Dose Drug Combinations Electron Spin Resonance Spectroscopy Environment Evaluation Freezing Frequencies Future Goals Grant Human Hypoxia Image Imaging technology International Interview Laboratories Laws Lead Life Malignant Neoplasms Maps Measurement Measures Methodology Methods Modeling Molecular Mus NCI Center for Cancer Research Oxygen Papaverine Performance Pharmaceutical Preparations Pharmacotherapy Phase Physiologic pulse Protocols documentation Radiation Radiation Dose Unit Radiation therapy Recommendation Regenerative Medicine Research Resistance Resolution Scientist Small Business Innovation Research Grant Soft tissue sarcoma Structure Technology Testing Therapeutic Studies Time Tissue Engineering Tissues Translations Treatment Protocols Tumor Biology Tumor Tissue United States National Institutes of Health Universities Weight anticancer research base cancer imaging cancer therapy computerized data processing data acquisition design evidence base experience imager innovation instrument instrumentation mouse model phase 2 designs pre-clinical preclinical imaging preservation programs prototype radiation delivery radiation response response sarcoma side effect temporal measurement tool development touchscreen tumor tumor hypoxia user-friendly

项目摘要

Abstract This SBIR Phase II proposal is designed to advance the progress made during the SBIR Phase I project “Robust Small Animal Oxygen Imager to Model Enhanced Cancer Treatment”. During Phase I, we have developed a prototype of robust oxygen imager, JIVA-25, for preclinical cancer biology and radiation therapy research. In the current proposal, we plan improvements in hardware, software, and image acquisition methodology that will lead to reduced instrument weight, better instrument performance, and higher resolution oxygen maps. In addition, we will evaluate the JIVA-25 performance with cancer research animal studies that use radiation therapy and drug application. JIVA-25 is a 25 mT oxygen imager with small footprint based on the principles of electron paramagnetic resonance oxygen imaging. JIVA-25 can provide oxygen maps in tissues with 1 mm spatial resolution, 1 torr oxygen resolution and 1-10 min temporal resolution. No other competing method can provide accurate noninvasive pO2 maps with such precision. In tumor, accurate real-time pO2 maps will lead to oxygen guided radiation therapy (OGRT). OGRT is expected to reduce the delivered high radiation dose volume by lowering the dose to well-oxygenated tumor tissues. This will preserve the structure and integrity of irradiated tissues and reduce radiation side effects. The absence of preclinical (animal) oxygen imaging data is the major impediment in the development of evidence base for OGRT translation into clinics. The availability of oxygen maps in preclinical settings is also expected to lead to advanced drug and radiation therapies. Providing the research community with JIVA-25 instrument is the first step in achieving these goals.

抽象的该 SBIR 第二阶段提案旨在推进 SBIR 第一阶段项目“稳健”期间取得的进展用于模拟增强癌症治疗的小动物氧成像仪”。在第一阶段，我们开发了一种强大的氧气成像仪原型 JIVA-25，用于临床前癌症生物学和放射治疗研究。在当前的提案中，我们计划改进硬件、软件和图像采集方法，将减轻仪器重量、提高仪器性能和提高氧图分辨率。此外，我们将通过使用辐射的癌症研究动物研究来评估 JIVA-25 的性能治疗和药物应用。 JIVA-25 是一款基于电子顺磁原理的 25 mT 氧气成像仪，占地面积小 JIVA-25 可以提供 1 毫米空间分辨率、1 托的组织中的氧气图。没有其他竞争方法可以提供准确的氧气分辨率和 1-10 分钟时间分辨率。具有如此精确度的无创 pO2 图在肿瘤中，准确的实时 pO2 图将导致氧气引导。放射治疗 (OGRT) 预计可通过降低放射剂量来减少所传递的高放射剂量。充分氧化的肿瘤组织的剂量这将保持受照射组织的结构和完整性。并减少辐射副作用。缺乏临床前（动物）氧成像数据是主要的。 OGRT 转化为临床的基础证据的发展存在障碍氧气的可用性。临床前环境中的图谱也有望带来先进的药物和放射疗法。研究界使用 JIVA-25 仪器是实现这些目标的第一步。